Nifurtimox-Eflronithine Combination Treatment (NECT)

ApprovedSmall molecule

Nifurtimox-Eflronithine Combination Treatment (NECT) is one of 5 small molecule programs targeting Human African Trypanosomiasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Human African TrypanosomiasisActive, not recruiting

Human African TrypanosomiasisApproved

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Human African Trypanosomiasis

#DrugCompanyPhaseTrials

Lampit

Bayer

Phase 3

2 2

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Phase 3

2 3

Fexinidazole

Sanofi

Phase 3

6 4

Nifurtimox-Eflronithine Combination Treatment (NECT)

DDrugs for Neglected Diseases

Approved

1 5

Acoziborole

DDrugs for Neglected Diseases

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Human African Trypanosomiasis1 trial

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase

Completed·DDrugs for Neglected Diseases·Phase 4·NCT00906880·630 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nifurtimox-Eflronithine Combination Treatment (NECT). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nifurtimox-Eflronithine Combination Treatment (NECT) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nifurtimox-Eflronithine Combination Treatment (NECT). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Drugs for Neglected Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: DDrugs for Neglected Diseases

Nifurtimox-Eflronithine Combination Treatment (NECT)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Human African Trypanosomiasis1 trial

References

Drug Info

Quick Facts

Related News